A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

Inclusion Criteria: * Diagnosis of RMS * At least two documented clinical relapses within the last 2 years prior to screening, or one clinical relapse in the year prior to screening. No relapse 30 days prior to screening and at baseline * Participants must be neurologically stable for at least 30 days prior to randomization and baseline * EDSS score, at screening and baseline, from 0 to 5.5 inclusive * Average T25FWT score over two trials at screening and over two trials at baseline respectively, up to 150 (inclusive) seconds * Average 9HPT score over four trials at screening and over four trials at baseline respectively, up to 250 (inclusive) seconds * Documented magnetic resonance imaging (MRI) of brain with abnormalities consistent with MS at screening * Participants requiring symptomatic treatment for MS and/or physiotherapy must be treated at a stable dose. No initiation of symptomatic treatment for MS or physiotherapy within 4 weeks of randomization * Females of childbearing potential, agreement to remain abstinent or use adequate contraceptive methods * Female participants without reproductive potential may be enrolled e.g. if post-menopausal or if surgically sterile Exclusion Criteria: * History of primary progressive MS at screening * Any known or suspected active infection at screening or baseline (except nailbed infections), or any major episode of infection requiring hospitalization or treatment with IV antimicrobials within 8 weeks or treatment with oral antim…